MDxHealth SA (MDXH)
Market Cap | 111.60M |
Revenue (ttm) | 84.71M |
Net Income (ttm) | -41.95M |
Shares Out | 47.29M |
EPS (ttm) | -1.53 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 33,881 |
Open | 2.380 |
Previous Close | 2.400 |
Day's Range | 2.350 - 2.390 |
52-Week Range | 1.550 - 4.640 |
Beta | -391,052.41 |
Analysts | Strong Buy |
Price Target | 7.00 (+196.61%) |
Earnings Date | Nov 6, 2024 |
About MDXH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personaliz... [Read more]
Financial Performance
In 2023, MDxHealth's revenue was $70.19 million, an increase of 89.43% compared to the previous year's $37.05 million. Losses were -$43.10 million, -2.14% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MDXH stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 196.61% from the latest price.
News
MDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnos...
MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Michael K. McGarrity - Chief Executive Officer and Director Ron Kalfus - Chief Financial O...
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference c...
MDxHealth Announces Pricing of Offering of Ordinary Shares
MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commerc...
MDxHealth Announces Launch of Offering of Ordinary Shares
MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercia...
MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH) Q2 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - Wi...
MDxHealth Reports Q2 and Half Year 2024 Results
MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 million Year-over-year H1 revenues increase by 34% to 42.0 million Conference call with Q&A today at...
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRV...
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercia...
Mdxhealth Appoints Sanford J. Siegel, M.D.
Mdxhealth Appoints Sanford J. Siegel, M.D.
Mdxhealth to Present at Upcoming Investor Conferences
Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, t...
MDxHealth SA (MDXH) Q1 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH) Q1 2024 Results Conference Call May 1, 2024 8:30 AM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William...
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 million Increasing 2024 revenue guidance to $83-85 million, previously $...
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “md...
MDxHealth SA (MDXH) Q4 2023 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - Will...
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points o...
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
Mdxhealth Announces Resignation of Board Member
Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage pr...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDX...
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
NEWS RELEASE – REGULATED INFORMATION DECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM...
MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq
NEWS RELEASE – REGULATED INFORMATION NOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nas...
MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference
NEWS RELEASE November 14, 2023, 4PM ET/ 22:00 CET MDxHealth to Participate in the 35 th Annual Piper Sandler Healthcare Conference IRVINE, CA, and HERSTAL, BELGIUM – November 14, 2023 – MDxHealth SA (...
MDxHealth SA (MXDHF) Q3 2023 Earnings Call Transcript
MDxHealth SA (OTC:MXDHF) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference C...
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023
NEWS RELEASE – REGULATED INFORMATION 8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 IRVINE, CA, and ...
MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation
NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION NOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET